It is also important to note that the RNA Martini 3 models used in this work are still under development. While these prototype models have shown reasonable results in stabilizing LNP organization in the 'bleb' or inverted hexagonal assemblies (6A), they currently have limitations in accurately representing RNA structure and possible conformational changes induced by the lipid environment . Further development of the RNA models could provide better insights into how secondary structure and overall nucleobase content might influence LNP assembly and transfection efficiency. Presently, optimization efforts for LNP lipid components have been conducted separately from RNA sequence optimization. This separation, although necessary due to current limitations, underscores the need for more integrated approaches that can simultaneously account for both factors, ultimately leading to more effective LNP designs for drug delivery applications.